← All trials
NCT04629287
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2020
- Primary completion
- Dec 31, 2021
- Completion date
- Feb 28, 2022
- First posted
- Nov 16, 2020
- Last posted
- Nov 19, 2020
- Enrollment
- 102
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Kunming Pharmaceuticals, Inc.Lead sponsor
- Tianjin University of Traditional Chinese MedicineOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.